Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Autori principali: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
Elsevier
2019
|